PMID: 6985782Jan 1, 1980Paper

Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia

Annals of Internal Medicine
R StorbP L Weiden

Abstract

Thirty patients with severe aplastic anemia had no transfusions of blood products until just before marrow transplantation from HLA-identical family members. They were conditioned for grafting with cyclophosphamide, 50 mg/kg body weight on each of 4 successive days. All 30 had prompt initial marrow engraftment, which was sustained in 27. Twenty-five of the 30 are alive between 9 to 84 (median, 19.5) months. The actuarial projection of survival for 2 to 6 years is 75%. Twenty of the 25 surviving patients have no problems. Five have chronic graft-versus-host disease, resolving in two and active in three. Five patients died with infection or hemorrhage, four of whom had graft-versus-host disease. These data show that early transplantation should be carried out before transfusions are given for any patient with severe aplastic anemia who has an HLA-identical family member. If sensitization to minor transplantation antigens contained in blood products is avoided, the incidence of marrow-graft rejection will decrease, and survival will improve.

Citations

Jan 1, 1982·Gastrointestinal Radiology·M Schimmelpenninck, F Zwaan
Jan 1, 1984·Springer Seminars in Immunopathology·R Parkman
May 1, 1982·Indian Journal of Pediatrics·S StorchR P Gale
Nov 15, 2002·International Journal of Hematology·Ann E WoolfreyRainer Storb
Feb 1, 1981·Human Immunology·J A HansenE D Thomas
Nov 1, 1985·Human Immunology·E FerreiraR Pasquini
Jul 31, 1982·Lancet·E D ThomasR Storb
Oct 1, 1983·Clinics in Haematology·R Storb, G W Santos
Jul 18, 2002·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Masaharu KasaiAkio Kawamura
Sep 4, 1980·The New England Journal of Medicine·J A HansenE R Giblett
Mar 18, 1982·The New England Journal of Medicine·B M CamittaE D Thomas
Feb 28, 1985·The New England Journal of Medicine·A F ShieldsJ D Meyers
Dec 26, 2001·Current Opinion in Pediatrics·A WoolfreyR Storb
Aug 1, 1983·British Journal of Haematology·S A FeigR P Gale
Jul 1, 1995·British Journal of Haematology·J BarquineroC Rozman
Nov 6, 1982·British Medical Journal·H E Kay
Mar 1, 1981·Postgraduate Medical Journal·D SamsonC D Reid
Jan 1, 2009·Mediterranean Journal of Hematology and Infectious Diseases·Marco MarzialiGuido Lucarelli
Jun 16, 1992·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A PajorD Lehoczky
Jan 1, 1983·Critical Reviews in Clinical Laboratory Sciences·P L Weiden
Jan 1, 1984·Cancer Investigation·K M Sullivan, R Storb
Jan 23, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rajat KumarWael Saber
Oct 5, 2013·Transfusion Medicine Reviews·Seema R Patel, James C Zimring
Mar 1, 1984·Mayo Clinic Proceedings·R P Kadota, W A Smithson
Jul 1, 1985·Mayo Clinic Proceedings·E C RosenowF R Cockerill
Oct 1, 1992·Baillière's Clinical Haematology·N Sacchi
Mar 1, 1988·Transfusion Medicine Reviews·S J Slichter
Jun 1, 1988·Transfusion Medicine Reviews·D Ciavarella, E Snyder
Mar 31, 2009·Hematology/oncology Clinics of North America·Eva C Guinan
Nov 28, 2007·Blood Reviews·Guido Lucarelli, Javid Gaziev
Sep 1, 1982·AORN Journal·B C Mauldin
Apr 27, 2007·British Journal of Haematology·Julie A PanepintoUNKNOWN Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research
Apr 27, 2012·British Journal of Haematology·Lauri M BurroughsRainer Storb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.